Florida is currently home to 3753 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
Recruiting
Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and ev... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/05/2024
Locations: Morton Plant Hospital - BayCare, Clearwater, Florida
Conditions: Ischemic Heart Failure
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Recruiting
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Relapsed/Refractory B-cell Malignancies
Accelerated Resolution Therapy for Early Maladaptive Grief
Recruiting
The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Grief
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/05/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
Recruiting
Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/05/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Refractory Angina, Chronic Myocardial Ischemia
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Coral Gables, Florida
Conditions: Respiratory Syncytial Virus Infections
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
Recruiting
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2024
Locations: Keralty Hospital Miami, Miami, Florida
Conditions: Diabetic Foot Infection
Intermuscular Coherence as a Biomarker for ALS
Recruiting
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
08/02/2024
Locations: University of Miami Miller School of Medicine, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
08/02/2024
Locations: Nemours Children's Health, Orlando, Florida
Conditions: Juvenile Spondyloarthritis
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/02/2024
Locations: Arnold Palmer Hospital for Children, Orlando, Florida
Conditions: Medulloblastoma
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
08/02/2024
Locations: Arnold Palmer Hospital for Children, Orlando, Florida
Conditions: Neuroblastoma
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Recruiting
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2024
Locations: H. Lee Moffitt Cancer Center & Research Facility, Tampa, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic